Deloitte Technology Fast 500 Archives - Clinical ink Thu, 17 Oct 2024 17:21:08 +0000 en-US hourly 1 https://wordpress.org/?v=6.7.2 https://www.clinicalink.com/wp-content/uploads/2022/03/cropped-Clinical-Ink-Icon-Logo-32x32.png Deloitte Technology Fast 500 Archives - Clinical ink 32 32 Clinical ink Again Ranked Among Fastest-Growing Companies in North America on the 2022 Deloitte Technology Fast 500™ https://www.clinicalink.com/deloitte-techology-fast-500tm-2022/ Wed, 16 Nov 2022 10:40:46 +0000 https://www.clinicalink.com/?p=12880 Attributes 241% revenue growth to therapeutic expertise and technological innovation Horsham, Pennsylvania — Clinical ink, a global life science technology company, today announced its second […]

The post Clinical ink Again Ranked Among Fastest-Growing Companies in North America on the 2022 Deloitte Technology Fast 500™ appeared first on Clinical ink.

]]>
Attributes 241% revenue growth to therapeutic expertise and technological innovation

Horsham, Pennsylvania Clinical ink, a global life science technology company, today announced its second consecutive listing on the Deloitte Technology Fast 500™, a ranking of the 500 fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies in North America, now in its 28th year. Clinical ink grew 241% during this period.

Clinical ink Chief Executive Officer, Ed Seguine, attributes the company’s dramatic growth to expertise in collecting clinical data in highly complex and diverse therapeutic areas including Alzheimer’s, Parkinson’s, Neurology, and Immunology, as well as innovations in eSource technology including sensors, voice, and digital biomarkers.

Seguine said, “At Clinical ink, we are committed to powering patient outcomes by converging data, technology, and patient science. This recognition demonstrates our significant industry impact, as well as our thriving partnerships with the trusted customers and patients we serve. In our industry, many private companies exaggerate financial performance. Our appearance on the respected Deloitte Technology Fast 500 for two straight years is direct evidence of our significant growth and financial performance.”

This is the second year in a row that Clinical ink has been ranked.

Now in its 28th year, the Deloitte Technology Fast 500 provides a ranking of the fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies — both public and private — in North America. Technology Fast 500 award winners are selected based on percentage fiscal year revenue growth from 2018 to 2021.

About the 2022 Deloitte Technology Fast 500™

In order to be eligible for Technology Fast 500 recognition, companies must own proprietary intellectual property or technology that is sold to customers in products that contribute to a majority of the company’s operating revenues. Companies must have base-year operating revenues of at least US$50,000, and current-year operating revenues of at least US$5 million. Additionally, companies must be in business for a minimum of four years and be headquartered within North America.

About Clinical ink  

Clinical ink is the global life science company that brings data, technology, and patient science together. Our deep therapeutic-area expertise, coupled with Direct Data Capture, eCOA, eConsent, telehealth, neurocognitive testing, and digital biomarkers advancements, drive the industry standard for data precision and usher in a new generation of clinical trials. By harnessing digital data, we power sponsors, CROs, researchers, and patients to recenter decentralized trials and rewrite the clinical development experience.

The post Clinical ink Again Ranked Among Fastest-Growing Companies in North America on the 2022 Deloitte Technology Fast 500™ appeared first on Clinical ink.

]]>
Clinical Ink Ranked Among Fastest-Growing Company in North America on the Deloitte Technology Fast 500TM https://www.clinicalink.com/clinical-ink-ranked-among-fastest-growing-company-in-north-america-on-the-deloitte-technology-fast-500/ Wed, 17 Nov 2021 15:35:34 +0000 https://www.clinicalink.com/uncategorized/clinical-ink-ranked-among-fastest-growing-company-in-north-america-on-the-deloitte-technology-fast-500/ Attributes 293% Revenue Growth to technologies that simplify and accelerate complex clinical trial activities HORSHAM, Pa.; Nov. 17, 2021 (Business Wire) – Clinical Ink today […]

The post Clinical Ink Ranked Among Fastest-Growing Company in North America on the Deloitte Technology Fast 500<sup>TM</sup> appeared first on Clinical ink.

]]>
Attributes 293% Revenue Growth to technologies that simplify and accelerate complex clinical trial activities

HORSHAM, Pa.; Nov. 17, 2021 (Business Wire) – Clinical Ink today announced it ranked on the Deloitte Technology Fast 500™, a ranking of the 500 fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies in North America, now in its 27th year. Clinical Ink grew 293% during this period.

Clinical Ink’s Chief Executive Officer, Ed Seguine, credits the 293% growth to expertise in highly complex therapeutic areas (Alzheimers, Lupus, COVID) and novel execution models such as decentralized and remote trials. Seguine stated, “Clinical Ink has consistently delivered results for our customers and earned their trust. We’ve always been at the forefront of innovation with technologies that simplify and accelerate complex clinical trial activities. The recent acquisition of Digital Artefacts will drive future growth as we lead the next wave of innovation by simplifying the adoption of digital endpoints.”

About the 2021 Deloitte Technology Fast 500™
Now in its 27th year, the Deloitte Technology Fast 500 provides a ranking of the fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies — both public and private — in North America. Technology Fast 500 award winners are selected based on percentage fiscal year revenue growth from 2017 to 2020.

In order to be eligible for Technology Fast 500 recognition, companies must own proprietary intellectual property or technology that is sold to customers in products that contribute to a majority of the company’s operating revenues. Companies must have base-year operating revenues of at least US$50,000, and current-year operating revenues of at least US$5 million. Additionally, companies must be in business for a minimum of four years and be headquartered within North America.

Clinical Ink ranked No. 393 on the Deloitte Technology Fast 500™.

About Clinical Ink
Clinical Ink, a global clinical technology company, offers data certainty from source to submission. Our Lunexis™ eSource clinical technology and configurable direct data capture, eCOA, patient engagement, telehealth, eConsent, and instrumented data collection modules provide a suite of solutions for capturing and integrating electronic data from sites, clinicians, caregivers, and patients at its source. Clinical Ink’s therapeutic-area-specific approach to study design and data capture – with specific expertise in neurocognitive testing – enables more precise scales for cognitive and human factors assessments, including performance, behavior, movement, and all real-world activity.

About Deloitte
Deloitte refers to one or more of Deloitte Touche Tohmatsu Limited, a UK private company limited by guarantee (“DTTL”), its network of member firms, and their related entities. DTTL and each of its member firms are legally separate and independent entities. DTTL (also referred to as “Deloitte Global”) does not provide services to clients. In the United States, Deloitte refers to one or more of the US member firms of DTTL, their related entities that operate using the “Deloitte” name in the United States and their respective affiliates. Certain services may not be available to attest clients under the rules and regulations of public accounting. Please see www.deloitte.com/about to learn more about our global network of member firms.

The post Clinical Ink Ranked Among Fastest-Growing Company in North America on the Deloitte Technology Fast 500<sup>TM</sup> appeared first on Clinical ink.

]]>